0	0	1999-09-22	CD	O	O	B-Num
0	1	23	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	11	CD	O	B-NP	I-Num
0	4	MEDIMMUNE	NNP	O	I-NP	O
0	5	TO	TO	O	B-PP	O
0	6	ACQUIRE	NNP	O	B-NP	O
0	7	U.S.	NNP	O	I-NP	B-LocCoun
0	8	BIOSCIENCE	NNP	O	I-NP	B-Jour
0	9	FOR	IN	O	B-PP	O
0	10	$492	NN	O	O	B-Money
0	11	MILLION	NNP	O	O	B-Num

1	0	Medimmune	NNP	O	B-NP	B-Peop
1	1	Inc.	NNP	O	I-NP	I-Peop
1	2	COMMA	COMMA	O	O	O
1	3	a	DT	O	B-NP	O
1	4	biotechnology	NN	O	I-NP	O
1	5	company	NN	O	I-NP	B-OrgCorp
1	6	COMMA	COMMA	O	O	O
1	7	said	VBD	O	B-VP	O
1	8	Wednesday	NNP	O	B-NP	B-Date
1	9	that	IN	O	O	O
1	10	it	PRP	O	B-NP	O
1	11	had	VBD	O	B-VP	O
1	12	agreed	VBD	O	I-VP	O
1	13	to	TO	O	I-VP	O
1	14	acquire	VB	O	I-VP	O
1	15	U.S.	NNP	O	B-NP	B-LocCoun
1	16	Bioscience	NNP	O	I-NP	B-Jour
1	17	Inc.	NNP	O	I-NP	O
1	18	in	IN	O	B-PP	O
1	19	a	DT	O	B-NP	O
1	20	stock	NN	O	I-NP	O
1	21	swap	NN	O	I-NP	O
1	22	valued	VBN	O	B-VP	O
1	23	at	IN	O	B-PP	O
1	24	about	IN	O	O	O
1	25	$492	NN	O	B-NP	B-Money
1	26	million	CD	O	I-NP	B-Num
1	27	.	.	O	O	O

2	0	U.S.	NNP	O	B-NP	B-LocCoun
2	1	Bioscience	NNP	O	I-NP	B-Jour
2	2	COMMA	COMMA	O	O	O
2	3	based	VBN	O	B-VP	O
2	4	in	IN	O	B-PP	O
2	5	West	NNP	O	B-NP	B-Loc
2	6	Conshohocken	NNP	O	I-NP	I-Loc
2	7	COMMA	COMMA	O	O	O
2	8	Pa.	NNP	O	B-NP	B-Peop
2	9	COMMA	COMMA	O	O	O
2	10	is	VBZ	O	B-VP	O
2	11	developing	VBG	O	I-VP	O
2	12	drugs	NNS	O	B-NP	O
2	13	for	IN	O	B-PP	O
2	14	cancer	NN	O	B-NP	B-Medical
2	15	and	CC	O	O	O
2	16	AIDS	NNP	O	B-NP	B-Org
2	17	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	deal	NN	O	I-NP	O
3	2	is	VBZ	O	B-VP	O
3	3	the	DT	O	B-NP	O
3	4	latest	JJS	O	I-NP	O
3	5	in	IN	O	B-PP	O
3	6	a	DT	O	B-NP	O
3	7	wave	NN	O	I-NP	O
3	8	of	IN	O	B-PP	O
3	9	consolidation	NN	O	B-NP	O
3	10	sweeping	NN	O	O	O
3	11	the	DT	O	B-NP	O
3	12	biotechnology	NN	O	I-NP	O
3	13	industry	NN	O	I-NP	O
3	14	.	.	O	O	O

4	0	Increasingly	RB	O	O	O
4	1	COMMA	COMMA	O	O	O
4	2	large	JJ	O	B-NP	O
4	3	pharmaceutical	JJ	O	I-NP	B-Medical
4	4	companies	NNS	O	I-NP	B-OrgCorp
4	5	COMMA	COMMA	O	O	O
4	6	as	RB	O	O	O
4	7	well	RB	O	O	O
4	8	as	IN	O	O	O
4	9	some	DT	O	B-NP	O
4	10	of	IN	O	B-PP	O
4	11	the	DT	O	B-NP	O
4	12	few	JJ	O	I-NP	O
4	13	profitable	JJ	O	I-NP	O
4	14	biotechnology	NN	O	I-NP	O
4	15	concerns	NNS	O	I-NP	O
4	16	COMMA	COMMA	O	O	O
4	17	are	VBP	O	B-VP	O
4	18	buying	VBG	O	I-VP	O
4	19	up	IN	O	B-PP	O
4	20	smaller	JJR	O	B-NP	O
4	21	companies	NNS	O	I-NP	B-OrgCorp
4	22	to	TO	O	B-VP	O
4	23	add	VB	O	I-VP	O
4	24	new	JJ	O	B-NP	O
4	25	drug	NN	O	I-NP	B-Medical
4	26	candidates	NNS	O	I-NP	O
4	27	to	TO	O	B-PP	O
4	28	their	PP$	O	B-NP	O
4	29	product	NN	O	I-NP	O
4	30	pipelines	NNS	O	I-NP	O
4	31	.	.	O	O	O

5	0	For	IN	O	B-PP	O
5	1	companies	NNS	O	B-NP	B-OrgCorp
5	2	like	VBP	O	B-VP	O
5	3	Medimmune	NNP	O	B-NP	B-OrgCorp
5	4	COMMA	COMMA	O	O	O
5	5	which	WDT	O	B-NP	O
5	6	has	VBZ	O	B-VP	O
5	7	seen	VBN	O	I-VP	O
5	8	its	PP$	O	B-NP	O
5	9	share	NN	O	I-NP	O
5	10	price	NN	O	I-NP	O
5	11	more	JJR	O	O	O
5	12	than	IN	O	B-PP	O
5	13	quadruple	JJ	O	O	O
5	14	this	DT	O	B-NP	O
5	15	year	NN	O	I-NP	O
5	16	COMMA	COMMA	O	O	O
5	17	such	JJ	O	B-NP	O
5	18	deals	NNS	O	I-NP	O
5	19	are	VBP	O	B-VP	O
5	20	less	RBR	O	O	O
5	21	costly	JJ	O	O	O
5	22	and	CC	O	O	O
5	23	less	RBR	O	O	O
5	24	risky	JJ	O	O	O
5	25	than	IN	O	B-PP	O
5	26	developing	VBG	O	B-VP	O
5	27	new	JJ	O	B-NP	O
5	28	drugs	NNS	O	I-NP	O
5	29	from	IN	O	B-PP	O
5	30	scratch	NN	O	B-NP	O
5	31	.	.	O	O	O

6	0	The	DT	O	B-NP	O
6	1	year	NN	O	I-NP	O
6	2	began	VBD	O	B-VP	O
6	3	with	IN	O	B-PP	O
6	4	Warner-Lambert	NNP	O	B-NP	B-Peop
6	5	's	POS	O	B-NP	O
6	6	announcement	NN	O	I-NP	O
6	7	on	IN	O	B-PP	O
6	8	Jan.	NNP	O	B-NP	B-Date
6	9	26	CD	O	I-NP	I-Date
6	10	that	IN	O	O	O
6	11	it	PRP	O	B-NP	O
6	12	would	MD	O	B-VP	O
6	13	pay	VB	O	I-VP	O
6	14	$2.1	NN	O	B-NP	B-Money
6	15	billion	CD	O	I-NP	B-Num
6	16	for	IN	O	B-PP	O
6	17	Agouron	NNP	O	B-NP	B-OrgCorp
6	18	Pharmaceuticals	NNP	O	I-NP	I-OrgCorp
6	19	COMMA	COMMA	O	O	O
6	20	a	DT	O	B-NP	O
6	21	San	NNP	O	I-NP	B-LocCit
6	22	Diego	NNP	O	I-NP	I-LocCit
6	23	company	NN	O	I-NP	B-OrgCorp
6	24	with	IN	O	B-PP	O
6	25	a	DT	O	B-NP	O
6	26	single	JJ	O	I-NP	O
6	27	marketed	VBN	O	I-NP	O
6	28	AIDS	NNP	O	I-NP	B-Org
6	29	drug	NN	O	I-NP	B-Medical
6	30	and	CC	O	O	O
6	31	a	DT	O	B-NP	O
6	32	cancer	NN	O	I-NP	B-Jour
6	33	research	NN	O	I-NP	I-Jour
6	34	program	NN	O	I-NP	O
6	35	.	.	O	O	O

7	0	Since	IN	O	B-PP	O
7	1	then	RB	O	B-NP	O
7	2	COMMA	COMMA	O	O	O
7	3	Pharmacia	NNP	O	B-NP	B-OrgCorp
7	4	&	CC	O	I-NP	O
7	5	AMP	NNP	O	I-NP	B-OrgCorp
7	6	;	:	O	O	O
7	7	Upjohn	NNP	O	B-NP	B-OrgCorp
7	8	has	VBZ	O	B-VP	O
7	9	bought	VBN	O	I-VP	O
7	10	Sugen	NNP	O	B-NP	B-Peop
7	11	Inc.	NNP	O	I-NP	I-Peop
7	12	COMMA	COMMA	O	O	O
7	13	Abbott	NNP	O	B-NP	B-OrgCorp
7	14	Laboratories	NNP	O	I-NP	I-OrgCorp
7	15	has	VBZ	O	B-VP	O
7	16	bought	VBN	O	I-VP	O
7	17	Alza	NNP	O	B-NP	B-OrgCorp
7	18	COMMA	COMMA	O	O	O
7	19	which	WDT	O	B-NP	O
7	20	had	VBD	O	B-VP	O
7	21	itself	PRP	O	B-NP	O
7	22	acquired	VBD	O	B-VP	O
7	23	Sequus	NNP	O	B-NP	O
7	24	COMMA	COMMA	O	O	O
7	25	and	CC	O	O	O
7	26	Johnson	NNP	O	B-NP	B-Peop
7	27	&	CC	O	I-NP	O
7	28	AMP	NNP	O	I-NP	B-OrgCorp
7	29	;	:	O	O	O
7	30	Johnson	NNP	O	B-NP	B-Peop
7	31	has	VBZ	O	B-VP	O
7	32	acquired	VBN	O	I-VP	O
7	33	Centocor	NNP	O	B-NP	B-OrgCorp
7	34	.	.	O	O	O

8	0	Analysts	NNS	O	B-NP	B-ProfTitle
8	1	say	VBP	O	B-VP	O
8	2	there	EX	O	B-NP	O
8	3	will	MD	O	B-VP	O
8	4	be	VB	O	I-VP	O
8	5	many	JJ	O	O	O
8	6	more	RBR	O	O	O
8	7	such	JJ	O	O	O
8	8	deals	NNS	O	O	O
8	9	because	IN	O	O	O
8	10	drug	NN	O	B-NP	B-Medical
8	11	companies	NNS	O	I-NP	B-OrgCorp
8	12	are	VBP	O	B-VP	O
8	13	pressured	VBN	O	I-VP	O
8	14	to	TO	O	I-VP	O
8	15	increase	VB	O	I-VP	O
8	16	earnings	NNS	O	B-NP	O
8	17	faster	RBR	O	O	O
8	18	than	IN	O	O	O
8	19	they	PRP	O	B-NP	O
8	20	can	MD	O	B-VP	O
8	21	develop	VB	O	I-VP	O
8	22	new	JJ	O	B-NP	O
8	23	products	NNS	O	I-NP	O
8	24	.	.	O	O	O

9	0	Shares	NNS	O	B-NP	O
9	1	of	IN	O	B-PP	O
9	2	Medimmune	NNP	O	B-NP	B-OrgCorp
9	3	COMMA	COMMA	O	O	O
9	4	which	WDT	O	B-NP	O
9	5	is	VBZ	O	B-VP	O
9	6	based	VBN	O	I-VP	O
9	7	in	IN	O	B-PP	O
9	8	Gaithersburg	NNP	O	B-NP	B-Loc
9	9	COMMA	COMMA	O	O	O
9	10	Md.	NNP	O	B-NP	B-LocStat
9	11	COMMA	COMMA	O	O	O
9	12	closed	VBD	O	B-VP	O
9	13	Wednesday	NNP	O	B-NP	B-Date
9	14	at	IN	O	B-PP	O
9	15	$109.25	NN	O	B-NP	B-Money
9	16	COMMA	COMMA	O	O	O
9	17	up	IN	O	O	O
9	18	$7.1875	NN	O	B-NP	B-Money
9	19	COMMA	COMMA	O	O	O
9	20	on	IN	O	B-PP	O
9	21	Nasdaq	NNP	O	B-NP	O
9	22	.	.	O	O	O

10	0	Shares	NNS	O	B-NP	O
10	1	in	IN	O	B-PP	O
10	2	U.S.	NNP	O	B-NP	B-LocCoun
10	3	Bioscience	NNP	O	I-NP	B-Jour
10	4	COMMA	COMMA	O	O	O
10	5	closed	VBD	O	B-VP	O
10	6	at	IN	O	B-PP	O
10	7	$14.125	NN	O	B-NP	B-Money
10	8	COMMA	COMMA	O	O	O
10	9	up	IN	O	O	O
10	10	$2.625	NN	O	B-NP	B-Money
10	11	COMMA	COMMA	O	O	O
10	12	on	IN	O	B-PP	O
10	13	the	DT	O	B-NP	O
10	14	American	NNP	O	I-NP	B-LangRace
10	15	Stock	NNP	O	I-NP	O
10	16	Exchange	NNP	O	I-NP	O
10	17	.	.	O	O	O

11	0	Under	IN	O	B-PP	O
11	1	terms	NNS	O	B-NP	O
11	2	of	IN	O	B-PP	O
11	3	the	DT	O	B-NP	O
11	4	deal	NN	O	I-NP	O
11	5	COMMA	COMMA	O	O	O
11	6	Medimmune	NNP	O	B-NP	B-OrgCorp
11	7	will	MD	O	B-VP	O
11	8	exchange	VB	O	I-VP	O
11	9	0.15	CD	O	B-NP	B-Num
11	10	share	NN	O	I-NP	O
11	11	of	IN	O	B-PP	O
11	12	its	PP$	O	B-NP	O
11	13	stock	NN	O	I-NP	O
11	14	for	IN	O	B-PP	O
11	15	each	DT	O	B-NP	O
11	16	Bioscience	NNP	O	I-NP	B-Jour
11	17	share	NN	O	I-NP	O
11	18	.	.	O	O	O

12	0	``	``	O	O	O
12	1	This	DT	O	B-NP	O
12	2	acquisition	NN	O	I-NP	O
12	3	further	JJ	O	O	O
12	4	solidifies	NN	O	O	O
12	5	Medimmune	NNP	O	B-NP	B-OrgCorp
12	6	's	POS	O	B-NP	O
12	7	commitment	NN	O	I-NP	O
12	8	to	TO	O	B-PP	O
12	9	the	DT	O	B-NP	O
12	10	field	NN	O	I-NP	O
12	11	of	IN	O	B-PP	O
12	12	oncologyCOMMA	NN	O	B-NP	O
12	13	''	''	O	O	O
12	14	Wayne	NNP	O	B-NP	B-Peop
12	15	T.	NNP	O	I-NP	I-Peop
12	16	Hockmeyer	NNP	O	I-NP	I-Peop
12	17	COMMA	COMMA	O	O	I-Peop
12	18	Medimmune	NNP	O	B-NP	I-Peop
12	19	's	POS	O	B-NP	O
12	20	chairman	NN	O	I-NP	O
12	21	and	CC	O	I-NP	O
12	22	chief	NN	O	I-NP	B-ProfTitle
12	23	executive	NN	O	I-NP	B-ProfTitle
12	24	COMMA	COMMA	O	O	O
12	25	said	VBD	O	B-VP	O
12	26	in	IN	O	B-PP	O
12	27	a	DT	O	B-NP	O
12	28	statement	NN	O	I-NP	O
12	29	.	.	O	O	O

13	0	``	``	O	O	O
13	1	It	PRP	O	B-NP	O
13	2	will	MD	O	B-VP	O
13	3	provide	VB	O	I-VP	O
13	4	us	PRP	O	B-NP	O
13	5	with	IN	O	B-PP	O
13	6	three	CD	O	B-NP	B-Num
13	7	marketed	VBD	O	B-VP	O
13	8	products	NNS	O	B-NP	O
13	9	in	IN	O	B-PP	O
13	10	the	DT	O	B-NP	O
13	11	fields	NNS	O	I-NP	O
13	12	of	IN	O	B-PP	O
13	13	oncology	NN	O	B-NP	B-Jour
13	14	and	CC	O	I-NP	O
13	15	infectious	JJ	O	I-NP	O
13	16	disease	NN	O	I-NP	B-Medical
13	17	COMMA	COMMA	O	O	O
13	18	as	RB	O	O	O
13	19	well	RB	O	O	O
13	20	as	IN	O	O	O
13	21	development	NN	O	B-NP	O
13	22	capabilities	NNS	O	I-NP	O
13	23	and	CC	O	O	O
13	24	an	DT	O	B-NP	O
13	25	oncology	NN	O	I-NP	B-Jour
13	26	sales	NNS	O	I-NP	O
13	27	and	CC	O	I-NP	O
13	28	marketing	NN	O	I-NP	O
13	29	infrastructure	NN	O	I-NP	O
13	30	.	.	O	O	O
13	31	''	''	O	O	O

14	0	Founded	VBN	O	B-VP	O
14	1	in	IN	O	B-PP	O
14	2	1988	CD	O	B-NP	B-Date
14	3	COMMA	COMMA	O	O	O
14	4	Medimmune	NNP	O	B-NP	B-Peop
14	5	has	VBZ	O	B-VP	O
14	6	specialized	JJ	O	O	O
14	7	in	IN	O	B-PP	O
14	8	drugs	NNS	O	B-NP	O
14	9	for	IN	O	B-PP	O
14	10	infectious	JJ	O	B-NP	O
14	11	diseases	NNS	O	I-NP	O
14	12	and	CC	O	I-NP	O
14	13	organ	NN	O	I-NP	O
14	14	transplants	NNS	O	I-NP	O
14	15	.	.	O	O	O

15	0	Earlier	RBR	O	B-NP	O
15	1	this	DT	O	I-NP	O
15	2	year	NN	O	I-NP	O
15	3	the	DT	O	B-NP	O
15	4	company	NN	O	I-NP	B-OrgCorp
15	5	expanded	VBD	O	B-VP	O
15	6	its	PP$	O	B-NP	O
15	7	strategic	JJ	O	I-NP	O
15	8	focus	NN	O	I-NP	O
15	9	to	TO	O	B-VP	O
15	10	include	VB	O	I-VP	O
15	11	cancer	NN	O	B-NP	B-Medical
15	12	products	NNS	O	I-NP	O
15	13	with	IN	O	B-PP	O
15	14	the	DT	O	B-NP	O
15	15	acquisition	NN	O	I-NP	O
15	16	of	IN	O	B-PP	O
15	17	Vitaxin	NNP	O	B-NP	O
15	18	.	.	O	O	O

16	0	A	DT	O	B-NP	O
16	1	genetically-engineered	JJ	O	I-NP	O
16	2	antibody	NN	O	I-NP	B-Medical
16	3	designed	VBN	O	B-VP	O
16	4	to	TO	O	I-VP	O
16	5	prevent	VB	O	I-VP	O
16	6	tumors	NNS	O	B-NP	O
16	7	from	IN	O	B-PP	O
16	8	growing	VBG	O	B-VP	O
16	9	by	IN	O	B-PP	O
16	10	restricting	VBG	O	B-VP	O
16	11	their	PP$	O	B-NP	O
16	12	blood	NN	O	I-NP	O
16	13	supply	NN	O	I-NP	O
16	14	COMMA	COMMA	O	O	O
16	15	Vitaxin	NNP	O	B-NP	B-Peop
16	16	is	VBZ	O	B-VP	O
16	17	now	RB	O	O	O
16	18	in	IN	O	B-PP	O
16	19	the	DT	O	B-NP	O
16	20	second	NN	O	I-NP	B-Num
16	21	of	IN	O	B-PP	O
16	22	the	DT	O	B-NP	O
16	23	three	CD	O	I-NP	B-Num
16	24	phases	NNS	O	I-NP	O
16	25	of	IN	O	B-PP	O
16	26	clinical	JJ	O	B-NP	B-Medical
16	27	trials	NNS	O	I-NP	O
16	28	typically	RB	O	O	O
16	29	required	VBD	O	B-VP	O
16	30	for	IN	O	B-PP	O
16	31	new	JJ	O	B-NP	O
16	32	drugs	NNS	O	I-NP	O
16	33	by	IN	O	B-PP	O
16	34	the	DT	O	B-NP	O
16	35	Food	NNP	O	I-NP	B-Food
16	36	and	CC	O	I-NP	O
16	37	Drug	NNP	O	I-NP	B-Loc
16	38	Administration	NNP	O	I-NP	I-Loc
16	39	.	.	O	O	O

17	0	U.S.	NNP	O	B-NP	B-LocCoun
17	1	Bioscience	NNP	O	I-NP	B-Peop
17	2	's	POS	O	B-NP	O
17	3	product	NN	O	I-NP	O
17	4	portfolio	NN	O	I-NP	O
17	5	includes	VBZ	O	B-VP	O
17	6	Ethyol	NNP	O	B-NP	O
17	7	COMMA	COMMA	O	O	O
17	8	which	WDT	O	B-NP	O
17	9	is	VBZ	O	B-VP	O
17	10	approved	VBN	O	I-VP	O
17	11	for	IN	O	B-PP	O
17	12	the	DT	O	B-NP	O
17	13	reduction	NN	O	I-NP	O
17	14	of	IN	O	B-PP	O
17	15	cumulative	JJ	O	B-NP	O
17	16	kidney	NN	O	I-NP	O
17	17	toxicity	NN	O	I-NP	B-Medical
17	18	associated	VBN	O	B-VP	O
17	19	with	IN	O	B-PP	O
17	20	repeated	VBN	O	B-NP	O
17	21	chemotherapy	NN	O	I-NP	B-Jour
17	22	in	IN	O	B-PP	O
17	23	patients	NNS	O	B-NP	O
17	24	with	IN	O	B-PP	O
17	25	advanced	VBN	O	B-NP	O
17	26	ovarian	JJ	O	I-NP	B-Medical
17	27	cancer	NN	O	I-NP	B-Medical
17	28	and	CC	O	I-NP	O
17	29	non-small	JJ	O	I-NP	O
17	30	cell	NN	O	I-NP	O
17	31	lung	NN	O	I-NP	B-Medical
17	32	cancer	NN	O	I-NP	B-Medical
17	33	.	.	O	O	O

18	0	In	IN	O	B-PP	O
18	1	June	NNP	O	B-NP	B-Date
18	2	COMMA	COMMA	O	O	O
18	3	the	DT	O	B-NP	O
18	4	drug	NN	O	I-NP	B-Medical
18	5	was	VBD	O	B-VP	O
18	6	also	RB	O	I-VP	O
18	7	approved	VBN	O	I-VP	O
18	8	by	IN	O	B-PP	O
18	9	the	DT	O	B-NP	O
18	10	FDA	NNP	O	I-NP	O
18	11	for	IN	O	B-PP	O
18	12	use	VBP	O	B-NP	O
18	13	in	IN	O	B-PP	O
18	14	the	DT	O	B-NP	O
18	15	reduction	NN	O	I-NP	O
18	16	of	IN	O	B-PP	O
18	17	chronic	JJ	O	B-NP	B-Medical
18	18	dry	JJ	O	I-NP	B-Medical
18	19	mouth	NN	O	I-NP	I-Medical
18	20	in	IN	O	B-PP	O
18	21	patients	NNS	O	B-NP	O
18	22	undergoing	VBG	O	B-VP	O
18	23	radiation	NN	O	B-NP	O
18	24	treatment	NN	O	I-NP	O
18	25	for	IN	O	B-PP	O
18	26	head	NN	O	B-NP	O
18	27	and	CC	O	I-NP	O
18	28	neck	NN	O	I-NP	O
18	29	cancer	NN	O	I-NP	B-Medical
18	30	.	.	O	O	O

19	0	Other	JJ	O	B-NP	O
19	1	products	NNS	O	I-NP	O
19	2	include	VBP	O	B-VP	O
19	3	NeuTrexin	NNP	O	B-NP	O
19	4	COMMA	COMMA	O	O	O
19	5	which	WDT	O	B-NP	O
19	6	is	VBZ	O	B-VP	O
19	7	used	VBN	O	I-VP	O
19	8	to	TO	O	B-VP	O
19	9	treat	VB	O	I-VP	O
19	10	moderate-to-severe	JJ	O	B-NP	O
19	11	pneumocystis	NN	O	I-NP	O
19	12	carinii	NN	O	I-NP	O
19	13	pneumonia	NN	O	I-NP	B-Medical
19	14	in	IN	O	B-PP	O
19	15	patients	NNS	O	B-NP	O
19	16	with	IN	O	B-PP	O
19	17	compromised	VBN	O	B-NP	O
19	18	immune	JJ	O	I-NP	B-Medical
19	19	systems	NNS	O	I-NP	O
19	20	and	CC	O	O	O
19	21	is	VBZ	O	B-VP	O
19	22	in	IN	O	B-PP	O
19	23	clinical	JJ	O	B-NP	B-Medical
19	24	development	NN	O	I-NP	O
19	25	for	IN	O	B-PP	O
19	26	metastatic	JJ	O	B-NP	O
19	27	colorectal	JJ	O	I-NP	B-Medical
19	28	cancer	NN	O	I-NP	B-Medical
19	29	COMMA	COMMA	O	O	O
19	30	and	CC	O	O	O
19	31	Hexalen	NNP	O	B-NP	B-Peop
19	32	COMMA	COMMA	O	O	O
19	33	a	DT	O	B-NP	O
19	34	chemotherapy	NN	O	I-NP	B-Jour
19	35	used	VBD	O	B-VP	O
19	36	to	TO	O	I-VP	O
19	37	treat	VB	O	I-VP	O
19	38	patients	NNS	O	B-NP	O
19	39	with	IN	O	B-PP	O
19	40	persistent	JJ	O	B-NP	O
19	41	or	CC	O	I-NP	O
19	42	recurrent	JJ	O	I-NP	O
19	43	ovarian	JJ	O	I-NP	B-Medical
19	44	cancer	NN	O	I-NP	B-Medical
19	45	.	.	O	O	O

20	0	Lodenosine	NN	O	B-NP	O
20	1	is	VBZ	O	B-VP	O
20	2	in	IN	O	B-PP	O
20	3	clinical	JJ	O	B-NP	B-Medical
20	4	trials	NNS	O	I-NP	O
20	5	with	IN	O	B-PP	O
20	6	the	DT	O	B-NP	O
20	7	potential	NN	O	I-NP	O
20	8	to	TO	O	B-VP	O
20	9	treat	VB	O	I-VP	O
20	10	HIV	NNP	O	B-NP	O
20	11	infection	NN	O	I-NP	B-Medical
20	12	.	.	O	O	O
